Evidence map›Paper›PMID 37185409›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Longer Survival and Preserved Liver Function after Proton Beam Therapy for Patients with Unresectable Hepatocellular Carcinoma.

Takuto Nosaka, Hidetaka Matsuda, Ryotaro Sugata, Yu Akazawa, Kazuto Takahashi, Tatsushi Naito, Masahiro Ohtani, Kazuyuki Kinoshita, Tetsuya Tsujikawa, Yoshitaka Sato and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Takuto NosakaSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.ORCID 0000-0002-1929-7305
Hidetaka MatsudaSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.
Ryotaro SugataSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.
Yu AkazawaSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.
Kazuto TakahashiSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.
Tatsushi NaitoSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.
Masahiro OhtaniSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.
Kazuyuki KinoshitaDepartment of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.
Tetsuya TsujikawaDepartment of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.ORCID 0000-0002-8980-1044
Yoshitaka SatoProton Therapy Center, Fukui Prefecture Hospital, Fukui 910-8526, Japan.
Yoshikazu MaedaProton Therapy Center, Fukui Prefecture Hospital, Fukui 910-8526, Japan.ORCID 0000-0002-3040-5549
Hiroyasu TamamuraProton Therapy Center, Fukui Prefecture Hospital, Fukui 910-8526, Japan.
Yasunari NakamotoSecond Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.ORCID 0000-0002-3160-3555
University of Fukui · JPFukui Prefectural Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProton beam therapy (PBT) has been recently reported to achieve excellent tumor control with minimal toxicity in patients with unresectable hepatocellular carcinoma (HCC). Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) was investigated for larger HCC. This study was designed to evaluate the therapeutic effect of PBT on unresectable HCC in comparison with TACE combined with RFA.

methodsWe retrospectively analyzed 70 patients with HCC which was difficult to control by surgical resection or RFA monotherapy, 24 patients treated with PBT and 46 patients with TACE plus RFA. The therapeutic effects were assessed as local progression-free survival (PFS) and overall survival (OS).

resultsThe local PFS was more than 65% in 60 months for PBT and TACE plus RFA. The patients treated with PBT showed 82% OS at 60 months post-treatment. In contrast, those treated with TACE plus RFA showed 28% OS. When comparing the changes of ALBI scores in patients with different severities of chronic liver disease, the scores of PBT-treated patients were maintained at the baseline; however, those of TACE plus RFA-treated patients worsened after the treatments.

conclusionsThe results indicated that PBT may show better benefits than TACE plus RFA therapy in terms of OS in patients with unresectable HCC by sparing the non-tumor liver tissues.

Indexed as

Carcinoma, HepatocellularCatheter AblationChemoembolization, TherapeuticLiver NeoplasmsProton TherapyCombined Modality TherapyHumansRetrospective StudiesTreatment Outcomealbumin-bilirubin scorehepatocellular carcinomaproton beam therapyradiofrequency ablationtranscatheter arterial chemoembolization

Identifiers

PMID37185409
PMCPMC10136995
OpenAlexW4361279632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.